In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

Pemvidutide is a novel, peptide-based glucagon-like peptide-1/glucagon dual receptor agonist. The Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the ...

Pemvidutide: A Promising GLP-1/Glucagon Dual Receptor Agonist Pemvidutide stands out as Altimmune's flagship product, positioning the company uniquely in the competitive landscape of obesity and ...

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.

Merck & Co. says its dual GLP-1/glucagon receptor co-agonist efinopegdutide beat out Novo Nordisk's Ozempic in the tricky indication of nonalcoholic fatty liver disease (NAFLD). While NAFLD may be ...

About Pemvidutide Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.

For instance, glucagon-like peptide-1 (GLP-1) receptor agonists, which have made waves as therapies for diabetes and obesity, appear to hold promise for patients with MASLD and MASH, the authors said.

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Semaglutide (Ozempic, Wegovy), a GLP-1 receptor agonist approved for type 2 diabetes and obesity (conditions linked with increased risk for NAFLD and NASH), has shown some potential in mid-stage ...

The FDA granted fast track designation to efinopegdutide for the treatment of nonalcoholic steatohepatitis, according to a manufacturer’s press release.

The dual GLP-1 and glucagon receptor agonist resulted in 'striking' weight loss in a phase 2 dosing trial of people with overweight or obesity but without type 2 diabetes.